A small number of studies in humans treated with abatacept, a US Food and Drug Administration (FDA) approved biologic targeting T-cell costimulation through interruption of the B7/CD28 interaction,60 suggest similar mechanisms are relevant in patients with uveitis. This evidence concerns the gene CD28 and uveitis.